Table 1. Clinicopathological information of patients recruited in the MS experiments.
| Experiment No. | Patient ID | TMT Label | AJCC Stage | TNM Stage | Survival (month) |
DFI (month) | First Recurrence Site | Age (year) | Gender | Tumor differentiation | Adjuvant Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | G1 | 126 | IIIB | T4aN1bM0 | 75 | 75 | -- | 67 | M | Moderate | Mayo Clinic |
| G2 | 127 | IIIB | T3N1aM0 | 74 | 74 | -- | 63 | F | Moderate | FOLFOX4 | |
| P1 | 128 | IIIB | T4aN1bM0 | 32 | 13 | Liver | 53 | M | Well | FOLFOX4 | |
| P2 | 130 | IIIB | T3N1aM0 | 35 | 26 | Lung | 70 | F | Poor | FOLFOX4 | |
| 2 | G3 | 126 | IIIC | T4aN2aM0 | 70 | 70 | -- | 68 | F | Moderate | FOLFOX4 |
| G4 | 128 | IIIC | T4aN2aM0 | 66 | 66 | -- | 57 | M | Well | FOLFOX4 | |
| P3 | 130 | IIIC | T4aN2aM0 | 51 | 22 | Lung | 55 | M | Moderate | FOLFOX4 | |
| P4 | 131 | IIIC | T4aN2bM0 | 13 | 10 | Liver/Bone | 71 | M | Moderate | XELOX |
(Mayo Clinic regimen: 5-fluorouracil and leucovorin FOLFOX4 regimen: 5-fluorouracil, leucovorin and oxaliplatin.
XELOX regimen: capecitabine and oxaliplatin. Patient survival was defined as living time lasting from diagnosis of CRC to death or last follow-up. DFI was censored if the patient remained tumor recurrence free at the time of death or at the last follow-up)
DFI: disease-free interval.